newsfilter
← Latest News
PR Newswire·

Pulsenmore Announces Pricing of $7.5 Million Private Placement with a Single Healthcare Focused Institutional Investor

PLSM
  • Pulsenmore Ltd. (NASDAQ: PLSM; TASE: PLSM) entered a securities purchase agreement to sell 1,562,500 ordinary shares (or pre-funded warrants) and accompanying warrants in a private placement.
  • The combined purchase price is $4.80 per ordinary share (or $4.7999 for pre-funded warrants), representing a premium to the Nasdaq Minimum Price.
  • Gross proceeds from the offering are expected to be approximately $7.5 million before deducting commissions and expenses.
  • Ordinary warrants have an exercise price of $4.80, are exercisable immediately, and expire five years after issuance.
  • Pre-funded warrants have an exercise price of $0.0001, are exercisable immediately, and remain exercisable until fully utilized.
  • CEO Elazar Sonnenschein stated the financing will support commercial footprint expansion, particularly in the U.S., and drive long-term growth.
  • Closing of the offering is expected on or about June 26, 2026, subject to customary conditions.
  • Net proceeds will be used for marketing, commercialization activities, working capital, and general corporate purposes.
  • A.G.P./Alliance Global Partners acted as the sole placement agent for the offering.
  • The transaction relies on exemptions under Section 4(a)(2) of the Securities Act of 1933 and Regulation D.
  • Pulsenmore agreed to file a registration statement with the SEC to cover the resale of the ordinary shares and shares underlying the warrants.
  • The company is dedicated to home-use ultrasound technology for maternal health, connecting mothers and providers via telemedicine.